Zagar S, Löfler-Badzek D
Hospital for Tuberculosis and Pulmonary Diseases of Children and Adolescents, Zagreb, Yugoslavia.
ORL J Otorhinolaryngol Relat Spec. 1988;50(6):397-404. doi: 10.1159/000276020.
Fifty-one children aged 4-12 years, presenting with an acute epidose of chronic rhinosinusitis, were treated for 6 months with either Broncho-Vaxom (BV; marketed in Yugoslavia under the trade mark of Broncho-Munal) or placebo under double-blind randomized conditions. The efficacy of BV was assessed on the basis of clinical symptoms (cough, nasal discharge, congestion of nasal mucosa), number and duration of concomitant treatments (antibiotics, secretolytics, antitussives), number and duration of acute episodes during the trial and serum IgA levels. In BV treated patients the incidence and duration of infectious episodes and the number and duration of concomitant treatments decreased significantly in comparison with the placebo group, and the clinical response correlated positively with an increase in the serum levels of IgA. The results of treatment of acute episodes of chronic rhinosinusitis in children demonstrated the curative and prophylactic efficacy of BV.
51名4至12岁患有慢性鼻窦炎急性发作的儿童，在双盲随机条件下，接受了6个月的支气管疫苗（BV；在南斯拉夫以Broncho-Munal商标销售）或安慰剂治疗。根据临床症状（咳嗽、流鼻涕、鼻粘膜充血）、伴随治疗的次数和持续时间（抗生素、黏液溶解剂、镇咳药）、试验期间急性发作的次数和持续时间以及血清IgA水平评估BV的疗效。与安慰剂组相比，接受BV治疗的患者感染发作的发生率和持续时间以及伴随治疗的次数和持续时间显著降低，并且临床反应与血清IgA水平的升高呈正相关。儿童慢性鼻窦炎急性发作的治疗结果证明了BV的治疗和预防功效。
